Get the Stockscreener App
5.50
0.36%
-0.02
Pre-market:
5.44
-0.06
-1.09%
Curevac N V stock is traded at $5.50, with a volume of 1.46M.
It is down -0.36% in the last 24 hours and up +47.85% over the past month.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.
See More
Previous Close:
$5.52
Open:
$5.48
24h Volume:
1.46M
Relative Volume:
1.35
Market Cap:
$961.43M
Revenue:
$596.48M
Net Income/Loss:
$123.72M
P/E Ratio:
10.03
EPS:
0.5484
Net Cash Flow:
$106.59M
1W Performance:
+28.81%
1M Performance:
+47.85%
6M Performance:
+86.44%
1Y Performance:
+58.05%
1-Day Range:
$5.47
$5.575
1-Week Range:
$4.065
$5.72
52-Week Range:
$2.37
$5.72
Curevac N V Stock (CVAC) Company Profile
Compare CVAC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CVAC
Curevac N V
|
5.50 | 961.43M | 596.48M | 123.72M | 106.59M | 0.5484 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.99 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
508.86 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.71 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
540.71 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
254.09 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Curevac N V Stock (CVAC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-13-25 | Downgrade | Jefferies | Buy → Hold |
| Apr-25-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-08-23 | Initiated | SVB Securities | Outperform |
| Jan-19-23 | Upgrade | UBS | Neutral → Buy |
| Jan-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jan-21-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jan-18-22 | Initiated | JMP Securities | Mkt Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Hold |
| Jun-17-21 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-26-21 | Resumed | Credit Suisse | Underperform |
| Apr-26-21 | Initiated | Guggenheim | Neutral |
| Dec-10-20 | Downgrade | Credit Suisse | Neutral → Underperform |
| Sep-08-20 | Initiated | BofA Securities | Buy |
| Sep-08-20 | Initiated | Credit Suisse | Neutral |
| Sep-08-20 | Initiated | Jefferies | Hold |
View All
Curevac N V Stock (CVAC) Latest News
BioNTech SE Announces Acquisition of CureVac N.V. - TipRanks
Germany: BioNTech to acquire CureVac in all-stock transaction - Investors in Healthcare
BioNTech to Acquire CureVac in Strategic Move - TipRanks
CureVac agrees to pay Biontech termination fee Of $43.8 mln under specified circumstances - marketscreener.com
5 Stocks To Ride The German Market RallyCureVac (NASDAQ:CVAC), BioNTech (NASDAQ:BNTX) - Benzinga
BioNTech to Acquire CureVac in US$1.25 Billion All-Stock Transaction - Global Legal Chronicle
There's No Escaping CureVac N.V.'s (NASDAQ:CVAC) Muted Revenues Despite A 50% Share Price Rise - simplywall.st
CureVac’s SWOT analysis: mRNA pioneer’s stock faces pivotal year ahead By Investing.com - Investing.com Nigeria
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CVAC, KNW, SOAR, HLGN on Behalf of - Bluefield Daily Telegraph
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CVAC, KNW, SOAR, HLGN on Behalf of Shareholders - TradingView
BioNTech’s CureVac Deal Signals Deep Pivot Toward mRNA Cancer Therapies - Investing.com
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
BioNTech CureVac Acquisition Boosts Cancer Drug Pipeline - Industry Leaders Magazine
CureVac (CVAC) Receives Downgrade and Price Target Reduction fro - GuruFocus
BioNTech Announces Strategic Transaction to Acquire CureVac in Public Exchange Offer - GlobeNewswire
Jefferies cuts CureVac stock rating to hold on BioNTech acquisition By Investing.com - Investing.com UK
BioNTech: Oddo BHF raises target price - marketscreener.com
BioNTech to buy CureVac in USD 1.25 billion all-stock deal - Medical Dialogues
CureVac (CVAC) Downgraded by Jefferies Analyst After BioNTech Acquisition Agreement | CVAC Stock News - GuruFocus
BioNTech Announces Strategic Acquisition of CureVac - TipRanks
Biontech’s $1.25B Curevac buyout removes mRNA lawsuit uncertainty - BioWorld MedTech
BioNTech to Acquire CureVac in $1.25B Deal - USA Herald
BioNTech's Acquisition Of CureVac Brings Complementary Method To Target Cancer (BNTX) - Seeking Alpha
5 Firms Guide $1.25B BioNTech, CureVac Oncology Deal - Law360
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CVAC, SOAR, MTWO on Behalf of Shareholders - marketscreener.com
BioNTech to acquire CureVac in $1.25 billion all-stock deal By Investing.com - Investing.com South Africa
BioNTech to Acquire CureVac to Expand mRNA Cancer Therapies - N24.com.tr
BioNTech buys mRNA, courtroom rival CureVac in all-stock deal - BioPharma Dive
Watkins Advises on BioNTech’s US$1.25 Billion Acquisition of CureVac - Latham & Watkins LLP
M&A News: BioNTech (BNTX) Acquires CureVac in $1.25 Billion Deal - TipRanks
CureVac Stock Soars on BioNTech Buyout - Schaeffer's Investment Research
BioNTech Expands mRNA Cancer Portfolio With CureVac $1.25 Billion All-Stock Deal - Benzinga
BioNTech Buys CureVac For $1.25 Billion In Stock Deal - Finimize
CureVac, TELUS International, Oracle And Other Big Stocks Moving Higher On Thursday - Benzinga
COVID-19 Vaccine Maker BioNTech Buys CureVac as It Aims for Cancer Treatments - Investopedia
CureVac’s SWOT analysis: mRNA pioneer’s stock faces pivotal year ahead - Investing.com
BioNTech takes over CureVac in $1.25 billion all-stock deal among COVID rivals - marketscreener.com
Vaccine developer with Boston HQ acquired for $1.25B - NBC Boston
CureVac's SWOT analysis: mRNA pioneer's stock faces pivotal year ahead By Investing.com - Investing.com India
Sector Update: Health Care Stocks Lean Lower Premarket Thursday - marketscreener.com
BioNTech to Buy CureVac for $1.25 Billion for Cancer Boost - Bloomberg.com
M&A News: BioNTech Snaps Up CureVac in $1.25B Deal to Supercharge Cancer Pipeline - TipRanks
Germany's BioNTech to buy CureVac to boost cancer research - Yahoo
BioNTech to buy former Boston Covid vaccine rival for $1.25B - The Business Journals
CVAC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of CureVac N.V. Is Fair to Shareholders - Business Wire
BioNTech (BNTX) to Acquire CureVac in $1.25 Billion All-Stock Deal - GuruFocus
BioNTech, CureVac Agree to All-stock Purchase Deal - marketscreener.com
Oracle and CureVac rise premarket; Boeing and GameStop fall By Investing.com - Investing.com UK
BioNTech to Buy CureVac in All-Stock Deal - marketscreener.com
CureVac stock soars about 30% after BioNTech agrees to acquire co - Investing.com Australia
BioNTech To Acquire CureVac In All-stock Deal With Aggregate Equity Value Of Approx. $1.25 Bln - Nasdaq
Curevac N V Stock (CVAC) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):